- Home
- DBVT vs UMAC Comparison
DBVT vs UMAC Comparison
Compare DBVT & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- UMAC
- Stock Information
- Founded
- DBVT 2002
- UMAC 2019
- Country
- DBVT France
- UMAC United States
- Employees
- DBVT N/A
- UMAC N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- UMAC
- Sector
- DBVT Health Care
- UMAC
- Exchange
- DBVT Nasdaq
- UMAC Nasdaq
- Market Cap
- DBVT 102.0M
- UMAC 93.3M
- IPO Year
- DBVT N/A
- UMAC 2024
- Fundamental
- Price
- DBVT $6.46
- UMAC $6.15
- Analyst Decision
- DBVT Strong Buy
- UMAC Strong Buy
- Analyst Count
- DBVT 2
- UMAC 3
- Target Price
- DBVT $22.50
- UMAC $14.00
- AVG Volume (30 Days)
- DBVT 1.1M
- UMAC 783.6K
- Earning Date
- DBVT 05-06-2025
- UMAC 03-27-2025
- Dividend Yield
- DBVT N/A
- UMAC N/A
- EPS Growth
- DBVT N/A
- UMAC N/A
- EPS
- DBVT N/A
- UMAC N/A
- Revenue
- DBVT $4,200,000.00
- UMAC $5,565,319.00
- Revenue This Year
- DBVT $1,679.52
- UMAC N/A
- Revenue Next Year
- DBVT $535.67
- UMAC $80.62
- P/E Ratio
- DBVT N/A
- UMAC N/A
- Revenue Growth
- DBVT N/A
- UMAC N/A
- 52 Week Low
- DBVT $0.44
- UMAC $0.98
- 52 Week High
- DBVT $7.28
- UMAC $23.62
- Technical
- Relative Strength Index (RSI)
- DBVT 65.77
- UMAC 39.59
- Support Level
- DBVT $3.91
- UMAC $6.60
- Resistance Level
- DBVT $7.28
- UMAC $7.35
- Average True Range (ATR)
- DBVT 0.60
- UMAC 0.72
- MACD
- DBVT 0.20
- UMAC 0.13
- Stochastic Oscillator
- DBVT 75.67
- UMAC 23.11
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.